Vernalis Share Discussion Threads

[bountyhunter] 21/2/2017 07:18

also from the interims...

"The Company announced in February 2017 that Corvus Pharmaceuticals Inc had reached the predefined criteria for expansion of the cohort of patients with renal cell carcinoma treated with single-agent CPI-444 in the ongoing Phase 1/1b study. The expansion of this study triggered a $3 million milestone payment to Vernalis under the licensing deal with Corvus. Promising evidence of single-agent activity has also been seen in patients in other disease-specific cohorts, including lung cancer and melanoma
...

[bountyhunter] 21/2/2017 07:13

interims announced...

Ian Garland, Chief Executive Officer, commented,

"We are encouraged with the progress we have made in the last six months as we continued to expand our sales and saw further progress in our cough cold development pipeline.

"Midway through the 2016/17 cough cold season we have seen Tuzistra(R) XR prescriptions continue to grow steadily. We believe the emergence of high performing sales representatives in all regions across the US validates the market potential for Tuzistra(R) XR. We are, however, still in the early stages of the launch and our focus for the second half of the season is to drive sales-force effectiveness and so further increase the proportion of high performing sales territories. With continued prescription growth expected, the annualised run-rate at the end of June 2017 should provide a more meaningful predictor of sales performance for future years.

"We expect to achieve a number of milestones from the remainder of the cough cold franchise in 2017, including potential approvals by FDA of CCP-07 and CCP-08. We also continue to seek other opportunities to leverage our US commercial infrastructure and remain very excited about the growth potential of the business."

Presentation & Conference Call

Vernalis management will host a presentation at 9.30am (UK) today at the offices of FTI Consulting 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. It will also be available via webcast at hxxp://www.vernalis.com/investor-centre/presentations-and-webcasts and www.cantos.com and via conference call, which can be joined by dialling: [phone], Passcode 5780976# Please contact Jack Bower at FTI consulting [phone] for details.

[romeike] 20/2/2017 15:31

Good results tomorrow ought to trigger a decent recovery in the share price here.

I think we are looking for some evidence that that Tuzistra XR will at the very least comfortably replace revenue that would previously have come from sales of Frovatriptan.

Yes, for the current year the recently announced milestone payment already more than achieves this, but Tuzistra XR will be a reliable, regular source of income that keeps growing over the long term.

I'm looking forward to any further information about the H2 launches that will fully utilise the sales team into which so much investment went last year.

Good luck all!

[bountyhunter] 20/2/2017 10:35

thanks for the reminder fhmktg - the Vernalis website could do with an update as I can't find key anticipated results dates anywhere there - if I could I'd a link to the header - the only reference to tomorrow's news seems to be in the RNS of 30-Jan:

"Vernalis plc (LSE: VER) announces that its unaudited interim results for the six months ended 31 December 2016 will be released on Tuesday, 21 February 2017."

[fhmktg] 20/2/2017 08:43

Tomorrow's numbers will only include the very early figures for Tuzistra this cold season, it will be the coverage of insurers, stock deliveries and the scrip build up numbers that will get my attention.Contracts with CVS and Walgreens and confirmation of an agreement for Moxatag would be a bonus.Fingers crossed for tomorrow.

[fhmktg] 17/2/2017 12:12

Buyers coming in ahead of the numbers next week?

[ffp] 15/2/2017 17:52

woody, what an excellent post, thank you.

[fhmktg] 15/2/2017 15:24

£100 million turnover would see me in long term profit.Success for the Cough and cold product range could do this ona five year view.....fact or fantasy?

[romeike] 14/2/2017 16:29

Bought another £7,000 under 30p. Even if this dips on results it is still a good buy at this price.

Tuzistra XR has several selling points that make it attractive, all the information is easily available.

It is also worth noting that the $3 million payment announced this morning is only the first in a potential $220m of payments due subject to milestones being reached.

I would also draw attention to the flu situation in the US this season which means if the sales team in the US have been doing their job properly we should see take up significantly increased compared to the launch season.

h##ps://www.cdc.gov/flu/weekly/usmap.htm

[woodcutter] 14/2/2017 12:23

I've been researching a number of pharma co's where the share price has fallen considerably recently and once again I'm finding a similar pattern on director emoluments.

For a business that turned over roughly £12m last year to see the directors taking out £1.7m in remuneration seems unacceptable to me. Noses in the trough comes to mind.

Garland was paid £865K of which £363K was bonus related. All the bonus payments were attributed to company product milestones nothing was realted to anything financial neither was it related to share price performance.

There's a total of 8 directors including the non execs for a business with £12m revenue. Woodford and Invesco need to pressure the board to show restraint.

I've no doubt there's potential here but it needs to be realised before these kind of awards are given.

One question that does seem obvious is what differentiates VER cold medication from the wider range of products already on the market?
(I know they do more than cold remedies but these seem to be at the forefront of immediate revenue generation)

It's now on my watch list but need to see greater revenue and stricter cost control otherwise there'll end up being a further placing. I await the results with anticipation.

woody

[fhmktg] 14/2/2017 09:55

Only a week to the results and good figures for Tuzistra should set the base for significant turnaround.

[bantam175] 14/2/2017 09:35

Great news. And we're below Fridays value?

[bountyhunter] 14/2/2017 07:41

RNS today...

"Vernalis achieves a $3 million milestone payment

from Corvus Pharmaceuticals Inc

Vernalis plc is pleased to announce the achievement of a clinical milestone from its collaboration with Corvus Pharmaceuticals Inc ("Corvus") triggering a payment of $3 million to Vernalis.

In February 2015, the Company licensed exclusive, worldwide rights to its adenosine receptor antagonist programme, CPI-444, for use in all therapeutic applications to Corvus, a US-based biotechnology company focused on developing novel immuno-oncology therapies.

CPI-444 is a patented small molecule that is now being evaluated in a Phase 1/1b trial in patients with advanced cancers. It is the lead molecule in Corvus' pipeline and is being developed both as a single agent and in combination therapy. The clinical trial utilizes an adaptive design that allows expansion of disease-specific cohorts upon reaching certain pre-defined endpoints.

Corvus announced positive data from its Phase 1/1b study in January 2017, having achieved the clinical study protocol criteria for expansion in the cohort of patients with renal cell carcinoma with single agent CPI-444. This study expansion triggers the first clinical milestone payment of $3 million under the licensing agreement. Corvus has stated that, if early findings are confirmed with longer follow up and a larger set of patients in this expanded study, a registration trial could commence by the end of 2017.

Corvus was launched through a $33.3 million Series A fundraising in 2014 by the founder and former senior management at Pharmacyclics Inc and it raised a further $74.8 million Series B fundraising in 2015 and $70.7 million via a US IPO in March 2016.

The licensing deal has the potential for Vernalis to earn approximately $220 million in milestones from all indications, subject to development, regulatory and sales milestones being achieved. In addition, there are mid-single digit royalties payable if a product reaches the market, with the potential to reach low-double digit royalties in certain circumstances..."

[romeike] 10/2/2017 14:06

The news about Suir was part of the reason for the unfortunate fall to 32p. The fact is that Vernalis already had all the product it needed for samples in hand but having a long term solution well ahead of launch this winter would be reassuring. Bad news could send this lower but with the low float the upside here I think is much greater. No reason why this can't go to 70-90p and I don't believe the product is expensive enough to warrant concern on the Trump front. good luck all.

[fhmktg] 10/2/2017 11:56

Should have said ' having read'

[fhmktg] 10/2/2017 11:55

Having areas the local press on the takeover of the Suir site it looks like a local entrepreneur with existing interests in Galway.Says they will be up and running within one month and concentrating on contract manufacture .I wold expect an announcement on Moxatag with the results later this month.That, plus some positive news on Tuzamet sales should give the share price a nudge Northwards.

[fhmktg] 09/2/2017 10:48

I would suspect that a supply agreement with Vernalis would be an important part of the overall deal. We should find out soon- good news for VER if it comes about!

[romeike] 09/2/2017 10:23

Facilities in Ireland operated by the defunt Suir pharma, who was producing Moxatag, have been taken over by IQ Pharmatek.

Does anyone know if this deal means IQ Pharmatek will be producing Moxatag or are they merely taking over the site?


h##ps://www.rte.ie/news/2017/0112/844426-iq-pharmatek-clonmel/

[romeike] 09/2/2017 10:19

There will be absolutely no excuses for bad prescribing levels given the heavy investment in the sales team and the extent of severe flu this past season. Of course upcoming results will only contain information about the start of the season but should be a good indicator regardless. Expecting a climb to at least 70p here if revenue is encouraging. EPS presented in sterling should be helped by USD:GBP fx in our favour.

[chrisdgb] 07/2/2017 12:00

Well, let us hope the interims out soon will give us an idea how the US sales asre going...........

[latifs100] 06/2/2017 20:29

£6.57 to break even. when will i learn!!!

[romeike] 31/1/2017 14:08

Just saying:

h##ps://www.cdc.gov/flu/weekly/usmap.htm

[barrie16] 31/1/2017 07:13

FFP
Wow your lucky, I need more than that to break even.

[ffp] 30/1/2017 17:17

Ho Ho, I am one of the B Biotec boys...£1.12 to see braekeven, had em a lot of years..

[fhmktg] 30/1/2017 16:06

Roll on!The details of weekly scrip issues for Tuzistra will be a good indicator of the marketability and pricing for the Tris products.That ten bagger might not be too far away!Dum spiro spero.